Latest News & Features
Big Pharma
Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network. 10 December 2020
Americas
New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR. 10 December 2020
Medtech
Flexicare infringed a breathing tube patent owned by New Zealand appliance maker Fisher & Paykel (F&P), the English High Court has ruled. 10 December 2020
Americas
The University of Southern Denmark has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5. 9 December 2020
Americas
Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4. 8 December 2020
Americas
The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission. 7 December 2020
Americas
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen. 7 December 2020
Americas
Abbott Laboratories must face allegations brought by Grifols Diagnostic and a Novartis subsidiary that its HIV testing products infringe a patent covering a method to create HIV proteins using recombinant DNA. 4 December 2020
Generics
Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market. 3 December 2020
Americas
Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”. 3 December 2020